Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A

Panlong Pharmaceutical announced on August 27 that it plans to use its own funds to repurchase shares through centralized bidding, for use in an employee stock ownership plan or equity incentive. The repurchase price will not exceed 35.92 yuan per share, and the total amount will be no less than 10 million yuan and no more than 20 million yuan.

Panlong Pharmaceutical announced on August 27 that it plans to distribute a cash dividend of 1 yuan, tax included, for every 10 shares to all shareholders, with an estimated total payout of 13.67 million yuan. In the first half of 2026, the company achieved revenue of 423 million yuan and net profit attributable to the parent of 42.38 million yuan.

The National Essential Drug List 2026 Edition officially took effect today, adding 48 varieties of Chinese patent medicines and bringing the total to 794. This is the first adjustment to the essential drug list since 2018. The expansion of Chinese patent medicines closely targets needs in common primary care diseases, chronic conditions of aging, pediatric care, and specialized therapeutic areas, while fully retaining mainstream blood-activating and stasis-removing injectables such as Danshen Injection and Xuesaitong, exceeding market expectations. Among the newly added varieties, exclusive products account for a large share, including over 20 exclusive varieties such as Yiling Pharmaceutical's Jieyu Chufan Capsules, Hansen Pharmaceutical's Simo Decoction Oral Liquid, Mayinglong's Babao Eye Ointment, and Panlong Pharmaceutical's Panlongqi Tablets. Multiple listed companies are optimistic about sales prospects after entering the essential drug list. A source at Mayinglong said Babao Eye Ointment generated over 28 million yuan in revenue in 2025, and after inclusion, primary healthcare institutions will be required to stock it. Panlong Pharmaceutical's core product Panlongqi Tablets will directly benefit from mandatory stocking requirements at secondary hospitals and above. Industry experts predict that newly included varieties will go through a process of tendering, hospital admission, and volume ramp-up, with incremental growth of at least 20 percent and possibly up to 50 percent, but will not have a significant impact on performance in the short term.